Latest One Wales decisions
- 08/03/2023
- Ustekinumab (Stelara®) for the treatment of inflammatory bowel disease in children (OW25)
-
-
-
Last review date: May 2024
- 08/03/2023
- Vedolizumab (Entyvio®) for the treatment of inflammatory bowel disease in children (OW24)
-
-
-
Last review date: May 2024
- 08/03/2023
- Infliximab for the treatment of refractory pulmonary sarcoidosis (OW23)
-
-
-
Last review date: May 2024
- 01/05/2024
- Dabrafenib and trametinib for anaplastic thyroid cancer (OW27)
-
-
-
Issue date: April 2024
- 01/05/2024
- Abiraterone for non-metastatic and locally advanced, high-risk, hormone-sensitive prostate cancer (OW20)
-
-
-
Last review date: April 2024
- 14/02/2024
- Bevacizumab for ovarian cancer (OW01)
-
-
-
Last review date: February 2024
- 14/02/2024
- Bendamustine and rituximab for mantle cell lymphoma (OW09)
-
-
-
Last review date: February 2024
- 14/02/2024
- Bendamustine and rituximab for indolent lymphomas (OW08)
-
-
-
Last review date: February 2024
- 14/02/2024
- Rituximab for interstitial lung disease (OW13)
-
-
-
Last review date: February 2024
- 08/11/2022
- Vonicog alfa (Veyvondi®) for on-demand treatment of bleeding episodes in children with von Willebrand Disease (OW19)
-
-
-
Last review date: November 2023
- 26/07/2021
- Adalimumab for paediatric intermediate, posterior and pan-uveitis (OW04)
-
-
-
Last review date: November 2023
- 26/07/2021
- Arsenic trioxide for high risk acute promyelocytic leukaemia (OW06)
-
-
-
Last review date: September 2023
- 26/07/2021
- Azacitidine for progressive angioimmunoblastic T-cell lymphoma (OW16)
-
-
-
Last review date: September 2023
- 24/05/2022
- Mepolizumab (Nucala®) for chronic eosinophilic pneumonia (OW15)
-
-
-
Last review date: August 2023
- 04/09/2023
- Dostarlimab (Jemperli®) for locally advanced rectal cancer (OW26)
-
-
-
Issue date: 03/08/2023
- 24/05/2022
- Rituximab for pemphigus and pemphigoid (OW10)
-
-
-
Last review date: July 2023
- 12/04/2022
- Sorafenib for acute myeloid leukaemia (AML) maintenance (OW18)
-
-
-
Last review date: June 2023
- 26/04/2023
- Rituximab for myasthenia gravis (OW12) - reassessment
-
-
-
Issue date: 26/04/2023
- 02/02/2023
- Vedolizumab (Entyvio®) for the treatment of ICI induced enterocolitis (OW22)
-
-
-
Issue date: 02/02/2023
- 02/02/2023
- Infliximab for the treatment of ICI induced enterocolitis (OW21)
-
-
-
Issue date: 02/02/2023